Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 08, 2021

SELL
$67.69 - $73.03 $493,121 - $532,023
-7,285 Closed
0 $0
Q2 2021

Jul 21, 2021

SELL
$63.47 - $69.35 $292,914 - $320,050
-4,615 Reduced 38.78%
7,285 $502,000
Q1 2021

Apr 20, 2021

SELL
$60.0 - $68.46 $449,520 - $512,902
-7,492 Reduced 38.63%
11,900 $769,000
Q4 2020

Jan 25, 2021

BUY
$56.65 - $64.55 $5,948 - $6,777
105 Added 0.54%
19,392 $1.13 Million
Q3 2020

Oct 08, 2020

SELL
$62.1 - $78.08 $16,767 - $21,081
-270 Reduced 1.38%
19,287 $1.22 Million
Q2 2020

Jul 20, 2020

BUY
$72.34 - $84.0 $106,846 - $124,068
1,477 Added 8.17%
19,557 $1.51 Million
Q1 2020

Apr 16, 2020

BUY
$62.63 - $80.22 $27,870 - $35,697
445 Added 2.52%
18,080 $1.35 Million
Q4 2019

Jan 13, 2020

BUY
$61.62 - $67.78 $280,062 - $308,060
4,545 Added 34.72%
17,635 $1.15 Million
Q3 2019

Oct 25, 2019

BUY
$62.51 - $69.0 $111,205 - $122,751
1,779 Added 15.73%
13,090 $830,000
Q2 2019

Jul 16, 2019

SELL
$61.87 - $69.38 $91,010 - $102,057
-1,471 Reduced 11.51%
11,311 $764,000
Q1 2019

Apr 18, 2019

SELL
$62.53 - $70.05 $73,785 - $82,659
-1,180 Reduced 8.45%
12,782 $0
Q4 2018

Jan 24, 2019

SELL
$60.54 - $79.0 $172,841 - $225,545
-2,855 Reduced 16.98%
13,962 $873,000
Q3 2018

Oct 11, 2018

SELL
$71.28 - $78.92 $4,633 - $5,129
-65 Reduced 0.39%
16,817 $1.3 Million
Q2 2018

Aug 20, 2018

SELL
$64.88 - $75.68 $11,029 - $12,865
-170 Reduced 1.0%
16,882 $1.2 Million
Q1 2018

Apr 11, 2018

BUY
$72.84 - $88.8 $46,981 - $57,276
645 Added 3.93%
17,052 $1.29 Million
Q4 2017

Jan 17, 2018

SELL
$71.15 - $83.52 $70,153 - $82,350
-986 Reduced 5.67%
16,407 $1.18 Million
Q3 2017

Oct 24, 2017

BUY
$72.11 - $85.47 $1.25 Million - $1.49 Million
17,393
17,393 $1.41 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Sky Investment Group LLC Portfolio

Follow Sky Investment Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sky Investment Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sky Investment Group LLC with notifications on news.